文献速递头颈介入US

良性甲状旁腺病变的微创治疗:基于结节特征的治疗疗效与安全性

Minimally Invasive Treatment for Benign Parathyroid Lesions: Treatment Efficacy and Safety Based on Nodule Characteristics.
PubMed 文献 · Korean J Radiol · 2020-08-04

本研究纳入27例甲状旁腺病变患者,评估超声引导下射频消融(RFA)或乙醇消融(EA)的疗效与安全性。RFA用于19例原发性或继发性甲状旁腺功能亢进患者,EA用于8例症状性无功能甲状旁腺囊肿患者。结果显示RFA对原发性甲状旁腺功能亢进及EA对囊肿有效,但对继发性甲状旁腺功能亢进作用有限。

要点

  • RFA后原发性甲状旁腺功能亢进患者结节体积显著缩小,7/11例血清PTH和钙降至正常。
  • RFA对继发性甲状旁腺功能亢进疗效有限,仅3/8例血清PTH有治疗反应。
  • EA可显著缩小症状性无功能甲状旁腺囊肿,但可出现短暂声嘶。

关键影像表现/征象

  • 原发性甲状旁腺功能亢进患者RFA后6个月和12个月随访时结节大小和体积显著缩小(均p < 0.05)。
  • 7个结节几乎完全消失(残留体积< 0.1 mL)。
  • 症状性无功能甲状旁腺囊肿患者EA后末次随访时囊肿大小和体积显著缩小(均p < 0.05)。

诊断标准与关键数值

  • 原发性甲状旁腺功能亢进患者RFA后7/11例(63.6%)血清PTH和钙水平降至正常范围。
  • 原发性甲状旁腺功能亢进患者RFA后4/11例(36.4%)血清PTH和钙水平部分下降。
  • 继发性甲状旁腺功能亢进患者RFA后6个月内3/8例(37.5%)血清PTH有治疗反应,5/8例(62.5%)持续存在甲状旁腺功能亢进。

临床应用与阅片要点

  • RFA可用于原发性甲状旁腺功能亢进患者,术后需监测血清PTH和钙水平以评估治疗反应。
  • EA可用于症状性无功能甲状旁腺囊肿,随访中观察囊肿大小和体积变化。
  • 继发性甲状旁腺功能亢进患者RFA后可能持续存在甲状旁腺功能亢进,需注意评估疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study aimed to evaluate the efficacy and safety of ultrasound (US)-guided minimally invasive treatment in patients with parathyroid lesions.

MATERIALS AND METHODS: This study included 27 patients who had undergone US-guided radiofrequency ablation (RFA) or ethanol ablation (EA) for parathyroid lesions between January 2010 and 2018. RFA was performed in 19 patients with primary hyperparathyroidism (PHPT, n = 11) or secondary hyperparathyroidism (SHPT, n = 8), and EA was performed in eight patients with symptomatic nonfunctioning parathyroid cysts (SNPCs). Nodule size, volume, serum parathyroid hormone (PTH) and calcium levels were recorded before and after treatment. Complications were evaluated during and after treatment.

RESULTS: In patients with PHPT, significant reductions in size and volume were noted after RFA at 6- and 12-month follow-up (all, p < 0.05). Seven nodules nearly completely disappeared (residual volume < 0.1 mL); serum PTH and calcium levels were reduced to normal ranges (7/11, 63.6%). Four patients experienced partial reductions of serum PTH and calcium levels (4/11, 36.4%). In patients with SHPT, three experienced therapeutic response of serum PTH (3/8, 37.5%), while five showed persistent hyperparathyroidism (5/8, 62.5%) within 6 months after RFA. In patients with SNPCs, EA resulted in significant reductions in cyst size and volume (all, p < 0.05) at the last follow-up. A total of four complications (two transient hypocalcemia [RFA], one permanent [RFA], and one transient [EA] hoarseness) were observed.

CONCLUSION: Minimally invasive treatments, such as RFA and EA, may serve as therapeutic alternatives for patients with PHPT or SNPCs; they may have limited usefulness in patients with SHPT.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Ha EJ, Baek JH, Baek SM, et al. Minimally Invasive Treatment for Benign Parathyroid Lesions: Treatment Efficacy and Safety Based on Nodule Characteristics. Korean J Radiol. 2020. PMID: 32767864. doi:10.3348/kjr.2020.0037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。